The first and only Chinese-funded IV solution manufacturer that passed Japan PMDA GMP inspection
Founded in 1996, Kelun is one of the leading pharmaceutical companies in China, focusing on the R&D of innovative small molecules, biologics, generics, and new drug delivery system (NDDS). With more than 100 domestic and overseas subsidiaries, Kelun has established an integrated industrial chain of drug R&D, API fermentation / synthesis, formulation development, drug packaging, marketing and sales. Certified by the latest Chinese GMP standards, Kelun's 25 production lines manufacture large/small volume injectables, lyophilized powder, solid/liquid oral drugs, eye drops, and topical medication, which are highly needed in daily clinical practice.
Kelun has actively implemented an international strategy. Its leading products have achieved batch exports, enjoying a good reputation in over 40 countries and territories.
In August 2018, Kelun acquired the GMP Compliance Inspection Result Notification of PMDA (Japanese Pharmaceuticals and Medical Devices Agency). Kelun is the
first and only Chinese-funded IV solution manufacturer that passed Japan PMDA GMP inspection. In November, Kelun's IV solution products exported to Japan, indicating that Kelun's products entering into the high-end international market.